Autobio Diagnostics intends to invest CNY100 million to expand in vitro diagnostic industry layout

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe III Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Suzhou JinHe Fund") as a limited partner, with a subscription amount of RMB 100 million, the source of funds is the company's own funds, and signed the "Partnership Agreement of Suzhou JinHe III Equity Investment Partnership (Limited Partnership)" and "Supplementary Agreement" with the relevant partners on July 26, 2023, and the company will continue to invest in Suzhou JinHe Fund for the next five years, and the company will also participate in the investment in Suzhou JinHe Fund for the next five years, and the company will continue to invest in the investment in Suzhou JinHe Fund.

It is reported that the target fundraising scale of Suzhou JinHe Fund is CNY 1.915 billion, this industrial investment fund has not yet completed the fundraising, as of the date of signing the partnership agreement, the subscribed capital contribution of CNY 579 million, including the company's subscription amount of CNY 100 million. 

The investment scope is medical devices, biopharmaceuticals, biotechnology and medical service related fields. The investment strategy adopted is mainly based on in vitro diagnostics, with multiple strategies to build industry leading enterprises. Investment methods include equity investment and debt investment convertible to equity ("convertible bonds") with the ultimate purpose of equity investment.

Autobio said that the company's investment in the biomedical industry fund is a strategic exploration based on the long-term development of the company, on one hand, the company can take advantage of the industry experience, resource advantages and management platform of professional investment institutions, to look for high-quality enterprises or projects in the field of biomedical related areas with core competitiveness, high growth or strong growth potential, to further expand the company's in vitro diagnostic field related to the industrial layout in line with the company's long-term strategy. 

This is in line with the Company's long-term development strategy. On the other hand, combining the fund manager's management experience and risk control system to help the Company grasp the investment opportunities is conducive to controlling the risks of investment and mergers and acquisitions and safeguarding the quality of investment projects, which is in line with the interests of the Company and its shareholders.